MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 17, 2004; DOI: 10.1124/mol.104.004614


0026-895X/05/6703-965-975$20.00
Mol Pharmacol 67:965-975, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.004614v1
67/3/965    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mollereau, C.
Right arrow Articles by Roumy, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mollereau, C.
Right arrow Articles by Roumy, M.
ORIGINAL ARTICLE

Neuropeptide FF (NPFF) Analogs Functionally Antagonize Opioid Activities in NPFF2 Receptor-Transfected SH-SY5Y Neuroblastoma Cells

Catherine Mollereau, Honoré Mazarguil, Jean-Marie Zajac, and Michel Roumy

Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique, Unité Mixte Recherche 5089, Toulouse, France

Abstract

To elucidate the mechanism of the cellular antiopioid activity of neuropeptide FF (NPFF), we have transfected the SH-SY5Y neuroblastoma cell line, which expresses µ-and {delta}-opioid receptors, with the human NPFF2 receptor. The selected clone, SH2-D9, expressed high-affinity NPFF2 receptors in the same range order as µ- and {delta}-opioid receptors (100–300 fmol/mg of protein). The NPFF analog [D-Tyr1, (NMe)Phe3]NPFF (1DMe) did not modify the binding parameters of the µ- and {delta}-specific agonists [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and deltorphin-I, respectively. 1DMe dose dependently inhibited 75 to 80% of the cAMP production stimulated by forskolin. Preincubation with 1DMe halved the maximal inhibition of N-type Ca2+ channels by opioid agonists. In the presence of carbachol, acting on muscarinic receptors to release Ca2+ from the intracellular stores, deltorphin-I and 1DMe enhanced this release. Preincubation with 1DMe reduced the maximal effect of deltorphin-I by 40%, demonstrating an antiopioid effect in this experimental model for the first time. By using peptides corresponding to the carboxyl terminus of the {alpha}i1,2, {alpha}i3, {alpha}o, and {alpha}s subunits of G proteins, which specifically uncouple receptors from G proteins, we demonstrated that µ-opioid and NPFF2 receptors couple to the four subunits assayed. The Ca2+ release from the intracellular stores by 1DMe resulted from the coupling of NPFF2 receptors with G{alpha}o and G{alpha}i1,2, whereas the coupling with G{alpha}s reduced the antiopioid effect of 1DMe in the modulation of N-type channels. This SH2-D9 cell line now provides the opportunity to study the interaction between both receptors.


Received July 6, 2004; accepted December 17, 2004

Address correspondence to: Dr. Michel Roumy, Institut de Pharmacologie et de Biologie Structurale, CNRS, UMR 5089, 205 route de Narbonne, 31077 Toulouse cedex 04, France. E-mail: michel.roumy{at}ipbs.fr




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Roumy, C. Lorenzo, S. Mazeres, S. Bouchet, J.-M. Zajac, and C. Mollereau
Physical Association between Neuropeptide FF and {micro}-Opioid Receptors as a Possible Molecular Basis for Anti-opioid Activity
J. Biol. Chem., March 16, 2007; 282(11): 8332 - 8342.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics